AU580005B2 - Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis - Google Patents

Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Info

Publication number
AU580005B2
AU580005B2 AU30977/84A AU3097784A AU580005B2 AU 580005 B2 AU580005 B2 AU 580005B2 AU 30977/84 A AU30977/84 A AU 30977/84A AU 3097784 A AU3097784 A AU 3097784A AU 580005 B2 AU580005 B2 AU 580005B2
Authority
AU
Australia
Prior art keywords
tigogenin
cellobioside
arteriosclerosis
treating hypercholesterolemia
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30977/84A
Other languages
English (en)
Other versions
AU3097784A (en
Inventor
M. Rene Malinow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Foundation of Oregon
Original Assignee
Medical Research Foundation of Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Foundation of Oregon filed Critical Medical Research Foundation of Oregon
Publication of AU3097784A publication Critical patent/AU3097784A/en
Application granted granted Critical
Publication of AU580005B2 publication Critical patent/AU580005B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
AU30977/84A 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis Ceased AU580005B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US602298 1984-04-20
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (2)

Publication Number Publication Date
AU3097784A AU3097784A (en) 1985-10-24
AU580005B2 true AU580005B2 (en) 1988-12-22

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30977/84A Ceased AU580005B2 (en) 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Country Status (16)

Country Link
US (1) US4602005A (cg-RX-API-DMAC7.html)
EP (1) EP0159431B1 (cg-RX-API-DMAC7.html)
JP (1) JPS60224697A (cg-RX-API-DMAC7.html)
KR (1) KR940002114B1 (cg-RX-API-DMAC7.html)
AT (1) ATE42959T1 (cg-RX-API-DMAC7.html)
AU (1) AU580005B2 (cg-RX-API-DMAC7.html)
CA (1) CA1246544A (cg-RX-API-DMAC7.html)
DE (1) DE3478114D1 (cg-RX-API-DMAC7.html)
DK (2) DK165839C (cg-RX-API-DMAC7.html)
ES (1) ES534553A0 (cg-RX-API-DMAC7.html)
FI (2) FI82253C (cg-RX-API-DMAC7.html)
HU (1) HUT37802A (cg-RX-API-DMAC7.html)
IE (1) IE58015B1 (cg-RX-API-DMAC7.html)
NO (1) NO842990L (cg-RX-API-DMAC7.html)
NZ (1) NZ208961A (cg-RX-API-DMAC7.html)
ZA (1) ZA845690B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
WO1993007167A1 (en) * 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
AU659506B2 (en) * 1991-11-25 1995-05-18 Pfizer Inc. Method for making steroidal peracyl glycosides
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
CA2138016A1 (en) * 1992-06-26 1994-01-06 Kathleen D. Goggin Steroidal beta-o-cellobioside heptaalkanoate process
CA2139104A1 (en) 1992-06-26 1994-01-06 Michael P. Deninno Steroidal glycosides for treating hypercholesterolemia
JP2566384B2 (ja) * 1992-06-26 1996-12-25 ファイザー・インコーポレーテッド ステロイダルペルアシル配糖体の合成法
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
CZ280195A3 (en) * 1993-04-28 1996-02-14 Pfizer Crystalline spirostanyl glycoside, monohydrate thereof, pharmaceutical composition based thereon and process for preparing crystalline steroidal glycoside
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
AU7250694A (en) * 1993-06-25 1995-01-17 Biosphere Technologies Inc. Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
WO1995018144A1 (en) * 1993-12-28 1995-07-06 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DE69943415D1 (de) * 1998-03-26 2011-06-16 Phytopharm Plc Godmanchester Sarsasapogenin und Smilagenin zur Behandlung kognitiver Störungen
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
NZ545332A (en) * 2001-01-26 2007-09-28 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265886A (en) * 1978-07-05 1981-05-05 Roecar Holdings (Netherlands Antilles (Nv) Spiroketalins and their applications
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265886A (en) * 1978-07-05 1981-05-05 Roecar Holdings (Netherlands Antilles (Nv) Spiroketalins and their applications
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia

Also Published As

Publication number Publication date
ATE42959T1 (de) 1989-05-15
DE3478114D1 (en) 1989-06-15
JPH0456840B2 (cg-RX-API-DMAC7.html) 1992-09-09
NO842990L (no) 1985-10-21
DK14892D0 (da) 1992-02-06
DK361084D0 (da) 1984-07-23
FI900531A0 (fi) 1990-02-02
DK14892A (da) 1992-02-06
DK165839C (da) 1993-06-21
FI842935L (fi) 1985-10-21
ES8601233A1 (es) 1985-11-16
FI842935A0 (fi) 1984-07-23
IE841904L (en) 1985-10-20
FI87792C (fi) 1993-02-25
FI87792B (fi) 1992-11-13
JPS60224697A (ja) 1985-11-09
EP0159431B1 (en) 1989-05-10
FI82253B (fi) 1990-10-31
AU3097784A (en) 1985-10-24
EP0159431A2 (en) 1985-10-30
EP0159431A3 (en) 1986-01-08
ZA845690B (en) 1986-03-26
FI82253C (fi) 1991-02-11
DK166213B (da) 1993-03-22
DK165839B (da) 1993-01-25
HUT37802A (en) 1986-02-28
KR850007432A (ko) 1985-12-04
KR940002114B1 (ko) 1994-03-17
NZ208961A (en) 1988-01-08
ES534553A0 (es) 1985-11-16
US4602005A (en) 1986-07-22
CA1246544A (en) 1988-12-13
DK166213C (da) 1993-08-16
DK361084A (da) 1985-10-21
IE58015B1 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
AU580005B2 (en) Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis
IE841991L (en) Steroids
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
IE891379L (en) Benzopyrido piperidine, piperidylidene and piperazine¹compounds
EP0326340A3 (en) Improvement in the synthesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione
KE3737A (en) N-naphthoylglycine derivatives
NZ236032A (en) Napthacenedione derivatives, their preparation and pharmaceutical compositions
ES8302733A1 (es) Un procedimiento para preparar nuevos derivados de antraci- clina
WO1993025568A3 (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
TW366264B (en) Herbicidal 3-substituted pyridine compounds and derivatives thereof
HU901678D0 (en) Process for the production of new 4'-epi-4'-amino-antacyclines
IE45756L (en) Process for the production of 2, 9-dioxatricyclo [4,3,1,0]¹decanes
EP0367671A3 (en) Novel beta-d-phenylthioxylosides, their method of preparation and their use as pharmaceuticals
CA2032311A1 (en) 2,19-methyleneoxy and 2,19-methylenethio bridged steroids as aromatase and 19-hydroxylase inhibitors
EP0324472A3 (en) Ketenedithioacetal derivatives and processes for producing the same as well as a composition containing the same
AU5512299A (en) Unsaturated oligophenol cyanates
JPS6468389A (en) Novel n-acetyl-beta-d-glucosamine derivative
EP0450073A4 (en) 1-azaindolizine derivative, intermediate for synthesis thereof, and antiallergic containing 1-azaindolizine derivative
AU563819B2 (en) Tricyclic nitrogen-containing diones
AU1799495A (en) Agent for prevention or alleviation of allergy sypmtoms

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired